Your browser does not fully support modern features. Please upgrade for a smoother experience.
Subject:
All Disciplines Arts & Humanities Biology & Life Sciences Business & Economics Chemistry & Materials Science Computer Science & Mathematics Engineering Environmental & Earth Sciences Medicine & Pharmacology Physical Sciences Public Health & Healthcare Social Sciences
Sort by:
Most Viewed Latest Alphabetical (A-Z) Alphabetical (Z-A)
Filter:
All Topic Review Biography Peer Reviewed Entry Video Entry
Topic Review
Techniques for DNA Methylation Testing in Glioblastomas
Epigenetic changes in DNA methylation contribute to the development of many diseases, including cancer. In glioblastoma multiforme, the most prevalent primary brain cancer and an incurable tumor with a median survival time of 15 months, a single epigenetic modification, the methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene, is a valid biomarker for predicting response to therapy with alkylating agents and also, independently, prognosis. The progress from single gene to whole-genome analysis of DNA methylation has allowed a better subclassification of glioblastomas.
  • 1.2K
  • 15 Jul 2022
Topic Review
C-Src and EGFR Inhibition
The proto-oncogene c-Src is a non-receptor tyrosine kinase playing a key role in many cellular pathways, including cell survival, migration and proliferation. c-Src de-regulation has been observed in several cancer types, making it an appealing target for drug discovery efforts. Recent evidence emphasizes its crucial role not only in promoting oncogenic traits, but also in the acquisition and maintenance of cancer resistance to various chemotherapeutic or molecular target drugs. c-Src modulates epidermal growth factor receptor (EGFR) activation and amplifies its downstream oncogenic signals.
  • 1.2K
  • 27 Sep 2020
Topic Review
Immunomodulation in Pancreatic Cancer
The majority of pancreatic cancer patients have a poor prognosis, where the five-year survival rate is 9% in the United States, with an increasing incidence rate of 1.03% per year. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer that makes up 90% of all diagnosed cases of pancreatic cancer. Other types of pancreatic cancer, such as neuroendocrine tumors, which secrete insulin, or acinar carcinomas, which release digestive enzymes, are less common. PDAC develops from neoplasms of the cells lining the pancreatic ducts and usually presents without symptoms until advanced stages of the disease. Here we discuss strategies for immunomodulation of pancreatic cancer.
  • 1.2K
  • 26 Nov 2020
Topic Review
Cancer-Associated Fibroblasts in Gastrointestinal Cancers
Gastrointestinal (GI) cancers are primary malignant tumors associated with cancer-related deaths worldwide. Although chemotherapy and radiotherapy are essential modalities to improve patient survival, many patients show resistance to these therapies. Various clinical studies have suggested that cancer-associated fibroblasts (CAFs) play a significant role in this resistance.
  • 1.2K
  • 23 Jun 2021
Topic Review
Tumor-Associated Trypsin Inhibitor (TATI)
TATI, also known as pancreatic secretory trypsin inhibitor (PSTI) or serine peptidase inhibitor Kazal 1 type (SPINK1), is a trypsin inhibitor that functions mainly in the pancreas, where it serves as a suppressor of premature trypsinogen activation.
  • 1.2K
  • 22 Sep 2021
Topic Review
Precision Anti-Cancer Medicines by Oligonucleotide in Clinical Reasearch
Oligonucleotide therapeutics enable a direct targeting of the gene by acting at the level of the RNA or at the level of the DNA, based on the Watson-Crick complementary rule of binding.
  • 1.2K
  • 29 Jul 2022
Topic Review
ICIs for Locally Advanced Resectable ESCC
Esophageal cancer has a high mortality rate and a poor prognosis, with more than one-third of patients receiving a diagnosis of locally advanced cancer. Esophageal squamous cell carcinoma (ESCC) is the dominant histological subtype of esophageal cancer in Asia and Eastern Europe. Although neoadjuvant or definitive chemoradiotherapy (CRT) has been the standard treatment for locally advanced ESCC, patient outcomes remain unsatisfactory, with recurrence rates as high as 30–50%. The combination of immune checkpoint inhibitors (ICIs) and CRT has emerged as a novel strategy to treat esophageal cancer, and it may have a synergistic action and provide greater efficacy.
  • 1.2K
  • 01 Nov 2022
Topic Review
The Adaptor Protein p66Shc
p66Shc is an adaptor protein with anti-mitogenic, anti-chemotactic, pro-apoptotic and pro-oxidant activities.  Neoplastic B cells from chronic lymphocytic leukemia (CLL) patients  have a profound deficiency in the expression of p66Shc which results in leukemic cell resistance to apoptosis and in an altered balance between homing and egress receptors that control B cell homing to and residency into the pro-survival lymphoid niche. Ablation of the gene encoding p66Shc in the Eμ-TCL1 mouse model of human CLL worsens disease presentation  by promoting leukemic cell invasiveness, providing in vivo evidence of the pathogenic role of the p66Shc defect in CLL pathogenesis. Here we briefly summarize the functions of p66Shc in lymphocytes, focalizing on the mechanisms exploited by p66Shc to control B cell trafficking and the abnormalities in this process caused by p66Shc deficiency in CLL. 
  • 1.2K
  • 12 Nov 2020
Topic Review
PDT
PDT has been approved by the United States Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer, esophageal cancer, and Actinic Keratoses, as well as age-related macular degeneration. Clinical trials have also demonstrated PDT efficacy for mesothelioma, prostate, bladder, brain cancer, and head and neck cancers as well as bacterial, fungal, and viral infections. In many cases, photosensitizing agents are also used off label with noted successes by clinicians who are comfortable with photomedicine and laser light delivery.
  • 1.2K
  • 02 Sep 2021
Topic Review
Flavonoids and Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition that severely reduces the quality of life of a considerable proportion of cancer patients. There is no cure for CIPN to date. Here, we explore the potential of flavonoids as pharmacological agents in combating CIPN. Flavonoids alleviate CIPN by reducing oxidative stress, inflammation, and neuronal damage, among other mechanisms.
  • 1.2K
  • 25 Apr 2021
Topic Review
Plasmonic Photothermal Therapy
The laser application for hyperthermia makes it possible to obtain managed thermal damage of tumor tissue. However, the small spatial selectivity of tumor tissue heating remains a problem of laser hyperthermia. The development of innovative nanoparticle-based technologies to improve the selectivity of laser heating is intensively pursued, and various types of plasmon resonance nanoparticles are used for this purpose, as follows: nanospheres nanoshells, nanorods, nanocages. Plasmonic photothermal therapy is referred to by the acronym PPT.
  • 1.2K
  • 11 Mar 2022
Topic Review
TP53 Mutations in Pancreatic Cancer Progression
The TP53 gene encodes a tumor suppressor protein. The TP53 gene is one of the most frequently mutated genes in humans. The TP53 protein is a transcription factor. TP53 can also influence the pancreatic ductal adenocarcinomas (PDAC) or colorectal cancer (CRC) microenvironment by influencing the expression of many genes. 
  • 1.2K
  • 08 Aug 2022
Topic Review
Therapies for Metastatic Thyroid Cancer
In this Review Article, we discuss the molecular landscape of thyroid cancer and the published and ongoing clinical studies focused on targeted therapies for advanced thyroid cancer. This article serves as a concise resource with up to date literature about this rapidly evolving field.
  • 1.2K
  • 24 Aug 2020
Topic Review
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
The presence of “hypoxic” tissue (with O2 levels of <0.1 mmHg) in solid tumours, resulting in quiescent tumour cells distant from blood vessels, but capable of being reactivated by reoxygenation following conventional therapy (radiation or drugs), have long been known as a limitation to successful cancer chemotherapy. This has resulted in a sustained effort to develop nitroaromatic “hypoxia-activated prodrugs” designed to undergo enzyme-based nitro group reduction selectively in these hypoxic regions, to generate active drugs. Such nitro-based prodrugs can be classified into two major groups; those activated either by electron redistribution or by fragmentation following nitro group reduction, relying on the extraordinary difference in electron demand between an aromatic nitro group and its reduction products. 
  • 1.2K
  • 22 Apr 2022
Topic Review
Paraneoplastic Leukocytosis in Cervical Cancer
Tumor-associated leukocytosis has been associated with poor prognosis in cervical cancer. Leukemoid reaction (i.e., white blood cell count > 40,000/μL) is defined paraneoplastic (PLR) when it occurs in the presence of a cytokine-secreting tumor (CST) without neoplastic bone marrow infiltration. Cervical cancers displaying PLR represent a peculiar entity characterized by a rapidly progressive behavior typically associated with chemo-radioresistance.
  • 1.2K
  • 30 Aug 2022
Topic Review
Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
Pathological lymph node involvement (pN1) after a pelvic lymph node dissection represents one of the most unfavorable prognostic factors for disease recurrence and cancer-specific mortality in prostate cancer. However, optimal management for pN1 patients remains unclear. Thus, the guideline from the European Association of Urology recommends discussing three following management options with pN1 patients after an extended pelvic lymph node dissection, based on nodal involvement characteristics: (i) offer adjuvant androgen-deprivation therapy, (ii) offer adjuvant androgen-deprivation therapy with additional radiotherapy and (iii) offer observation (expectant management) to a patient with ≤2 nodes and a prostate-specific antigen <0.1 ng/mL. Treatment intensification may reduce risks of recurrence and cancer-specific mortality, but it may increase adverse events and impair quality of life. Few randomized control trials for pN1 are under investigation. In addition, there are limited reports on the quality of life and patient-reported outcomes in patients with pN1. Therefore, more research is needed to establish an optimal therapeutic strategy for patients with pN1. 
  • 1.2K
  • 25 Jul 2022
Topic Review
Exosomes in Cancer Therapy
Exosomes are nano-vesicle-shaped particles secreted by various cells, including cancer cells.  Many studies have focused on the bioactive molecules that they export as exosomal cargo. These molecules can function as biomarkers in diagnosis or play a relevant role in modulating the immune system and in promoting apoptosis, cancer development and progression.
  • 1.2K
  • 22 Sep 2021
Topic Review
Tumor Suppressor WT1
The Wilms’ tumor 1 (WT1) gene was originally identified based on its mutational inactivation in Wilms’ tumor (nephroblastoma). This first discovery of WT1 as the responsible gene in an autosomal-recessive condition classified it as a tumor-suppressor gene. Mutations of WT1 were associated with the development of kidney tumors and urogenital defects.
  • 1.2K
  • 26 Jul 2021
Topic Review
Revisiting Hepatic Artery Infusion Chemotherapy
Hepatic artery infusion chemotherapy (HAIC) is a well-established and common treatment for advanced hepatocellular carcinoma (HCC), particularly in East Asia. However, HAIC is not recognized internationally. Although several trials have demonstrated the safety and efficacy of HAIC, evidence corroborating its overall survival (OS) benefits compared with standard treatments is insufficient. Nevertheless, HAIC may provide prominent benefits in selected patients such as patients with portal vein thrombosis or high intrahepatic tumor burden. Moreover, HAIC has been combined with several therapeutic agents and modalities, including interferon-alpha, multikinase inhibitors, radiation therapy, and immunotherapy, to augment its treatment efficacy. Most of these combinations appeared to increase overall response rates compared with HAIC alone, but results regarding OS are inconclusive. Two prospective randomized controlled trials comparing HAIC plus sorafenib with sorafenib alone have reported conflicting results, necessitating further research. As immunotherapy-based combinations became the mainstream treatments for advanced HCC, HAIC plus immunotherapy-based treatments also showed encouraging preliminary results. The trials of HAIC were heterogeneous in terms of patient selection, chemotherapy regimens and doses, HAIC combination agent selections, and HAIC technical protocols. These heterogeneities may contribute to differences in treatment efficacy, thus increasing the difficulty of interpreting trial results.
  • 1.2K
  • 29 Mar 2022
Topic Review
Neutrophils and Angiogenesis in Cancer
Tumor angiogenesis is one of the most critical steps in the progression of cancer. Owing to its fundamental role in tumor growth and metastasis, tumor angiogenesis is accepted to be a limiting factor and considered a powerful therapeutic target. Neutrophils contribute to the tumor progression via multiple mechanisms, ranging from the direct support of tumor cell survival to the immunosuppression. A strong body of evidence suggests that neutrophils also play a prominent role in tumor angiogenesis.
  • 1.2K
  • 29 Mar 2022
  • Page
  • of
  • 129
Featured Entry Collections
>>

Featured Reprints

>>
Encyclopedia of Digital Society, Industry 5.0 and Smart City
Encyclopedia of Engineering
Encyclopedia of Social Sciences
Encyclopedia of Medieval Royal Iconography
Academic Video Service
Feedback